{"protocolSection":{"identificationModule":{"nctId":"NCT00905255","orgStudyIdInfo":{"id":"LTS10888"},"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)","officialTitle":"A Randomized, Open Label, Parallel-group (One-step Titration and Two-step Titration), Multicenter 52-Week Study Followed by a 24-Week Extension Assessing the Safety and Tolerability of AVE0010 Monotherapy in Patients With Type 2 Diabetes","acronym":"GETGOAL-MONO"},"statusModule":{"statusVerifiedDate":"2016-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-05"},"primaryCompletionDateStruct":{"date":"2011-01","type":"ACTUAL"},"completionDateStruct":{"date":"2011-01","type":"ACTUAL"},"studyFirstSubmitDate":"2009-05-14","studyFirstSubmitQcDate":"2009-05-18","studyFirstPostDateStruct":{"date":"2009-05-20","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-08-18","resultsFirstSubmitQcDate":"2016-10-28","resultsFirstPostDateStruct":{"date":"2016-12-21","type":"ESTIMATED"},"dispFirstSubmitDate":"2012-02-21","dispFirstSubmitQcDate":"2012-02-21","dispFirstPostDateStruct":{"date":"2012-02-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-10-28","lastUpdatePostDateStruct":{"date":"2016-12-21","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) used as 2-step initiation regimen and 1-step initiation regimen in Japan, over a period of 24 weeks of treatment, followed by an extension up to Week 76.\n\nThe primary objective of this study is to evaluate the safety of lixisenatide once daily treatment in monotherapy at Week 24 by a descriptive comparison of a 1-step initiation and a 2-step initiation regimen in patients with type 2 diabetes in Japan.\n\nThe secondary objectives are to assess the overall safety of lixisenatide once daily treatment in monotherapy at Week 52 and Week 76; to assess the effects of lixisenatide on glycosylated hemoglobin (HbA1c) reduction at Week 52 and Week 76, body weight, and fasting plasma glucose (FPG); to assess pharmacokinetics (PK) and anti-lixisenatide antibody development."},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"],"keywords":["hyperglycemia","GLP-1"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":69,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Lixisenatide (Two-step Titration)","type":"EXPERIMENTAL","description":"2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.","interventionNames":["Drug: Lixisenatide (AVE0010)","Device: Pen auto-injector"]},{"label":"Lixisenatide (One-step Titration)","type":"EXPERIMENTAL","description":"1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to end of treatment.","interventionNames":["Drug: Lixisenatide (AVE0010)","Device: Pen auto-injector"]}],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","description":"Self administered by subcutaneous injections once daily within the hour preceding breakfast.","armGroupLabels":["Lixisenatide (One-step Titration)","Lixisenatide (Two-step Titration)"]},{"type":"DEVICE","name":"Pen auto-injector","armGroupLabels":["Lixisenatide (One-step Titration)","Lixisenatide (Two-step Titration)"],"otherNames":["OptiClik®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of the One-Step and Two-Step Titration Arms Assessed Through Adverse Events Collection and Vital Signs, Electrocardiogram (ECG) and Laboratory Monitoring","description":"Overview of adverse event profile is reported in terms of percentage of patients with treatment emergent adverse events (TEAEs) during the 24-week treatment period: any TEAE; any serious TEAE; any TEAE leading to death; and any TEAE leading to permanent treatment discontinuation.","timeFrame":"First dose of study drug up to 3 days after the last dose of study drug at Week 24 or early withdrawal"}],"secondaryOutcomes":[{"measure":"Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of All Patients During On-Treatment Period Assessed Through Adverse Events Collection and Vital Signs, ECG and Laboratory Monitoring","description":"Overview of adverse event profile is reported in terms of percentage of patients with TEAEs during the on-treatment period: any TEAE; any serious TEAE; any TEAE leading to death; any TEAE leading to permanent treatment discontinuation. The on-treatment period was the time from the first dose of study drug up to 3 days after the last dose at Week 76.","timeFrame":"First dose of study drug up to 3 days after the last dose of study drug at Week 76 or early withdrawal"},{"measure":"Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) for All Patients at Week 52 and 76","description":"Absolute change = HbA1c value at week of assessment (Week 52/Week 76) minus HbA1c value at baseline. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","timeFrame":"Baseline, Week 52, 76"},{"measure":"Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 52 and 76","description":"The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","timeFrame":"Week 52, 76"},{"measure":"Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 52 and 76","description":"The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","timeFrame":"Week 52, 76"},{"measure":"Change From Baseline in Body Weight for All Patients at Week 52 and 76","description":"Change was calculated by subtracting baseline value from value at week of assessment (Week 52/Week 76). The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","timeFrame":"Baseline, Week 52, 76"},{"measure":"Change From Baseline in Fasting Plasma Glucose (FPG) for All Patients at Week 52 and 76","description":"Change was calculated by subtracting baseline value from value at week of assessment (Week 52/Week 76). The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 1 day after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","timeFrame":"Baseline, Week 52, 76"}],"otherOutcomes":[{"measure":"Percentage of Patients Requiring Rescue Therapy","description":"Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values - from Week 4 to Week 8: fasting SMPG/FPG \\>270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\>8.5%, from Week 24 to end of treatment (Week 76): fasting SMPG/FPG \\>180 mg/dL (10.0 mmol/L) or HbA1c \\>8%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","timeFrame":"Baseline up to Week 52, Baseline up to Week 76"},{"measure":"Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia for the One-Step and Two-Step Titration Arms During 24-Week Treatment Period","description":"Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose less than 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.","timeFrame":"First dose of study drug up to 3 days after the last dose of study drug at Week 24 or early withdrawal"},{"measure":"Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia for All Patients During On-Treatment Period","description":"Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose less than 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.The on-treatment period was the time from the first dose of study drug up to 3 days after the last dose.","timeFrame":"First dose of study drug up to 3 days after the last dose of study drug at Week 76 or early withdrawal"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes mellitus, diagnosed for at least 2 months at the time of screening visit, not treated by an antidiabetic agent in the 3 months before screening, except treatment with sulfonylureas or alpha-glucosidase inhibitors at a stable dose. In this case the oral antidiabetic treatment must be discontinued before starting single-blind run-in phase\n\nExclusion Criteria:\n\n* HbA1c less than (\\<) 7 percent (%) or greater than (\\>) 10% at screening\n* At the time of screening age \\<legal age of majority\n* Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method\n* Type 1 diabetes mellitus\n* Type 2 diabetes treated by an antidiabetic pharmacological agent (except sulfonylurea or alpha-glucosidase inhibitors at a stable dose) within the 3 months preceding the screening. Insulin use is accepted if it is not within 3 months prior to screening visit and only for the following reasons: a) Prior insulin use for management of gestational diabetes; b) Short-term (less than or equal to \\[\\<=\\] 1 month) insulin use to maintain glycemic control for hospitalization, medical procedures, or intervention\n* FPG at screening \\>250 milligram per deciliter (mg/dL) (\\>13.9 millimole per liter \\[mmol/L\\])\n* Weight change of more than 5 kilogram (kg) during the 3 months preceding the screening visit\n* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease\n* History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening\n* Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to the time of screening\n* Within the last 6 months prior to screening: history of myocardial infarction, stroke, or heart failure requiring hospitalization\n* Known history of drug or alcohol abuse within 6 months prior to the time of screening\n* Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period\n* Uncontrolled or inadequately controlled hypertension at the time of screening with a resting supine systolic or diastolic blood pressure \\>180 millimeter of mercury (mmHg) or \\>95 mmHg, respectively\n* Laboratory findings at the time of screening: aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP): \\>2 times upper limit of the normal (ULN) laboratory range; amylase and/or lipase: \\>3 times ULN; total bilirubin: \\>1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin \\<11 gram/deciliter and/or neutrophils \\<1500 per cubic millimeter (mm\\^3) and/or platelets \\<100000/mm\\^3; positive test for Hepatitis B surface antigen (HBsAg) and/or Hepatitis C antibody (HCAb) and positive serum pregnancy test in females of childbearing potential\n* Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram (ECG) or vital signs at the time of screening that in the judgment of the investigator or any sub-investigator precludes safe completion of the study or constrains efficacy assessment\n* Patients who are considered by the investigator or any sub-investigator as inappropriate for this study for any reason (for example, impossibility to meet specific protocol requirements, such as scheduled visits, being able to do self-injections, likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol)\n* Patient is an investigator or any sub-investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol\n* Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 1 week or more within 3 months prior to the time of screening\n* Use of any investigational drug within 3 months prior to screening\n* Participation in a previous study with lixisenatide\n* End-stage renal disease as defined by a serum creatinine clearance of \\<15 milliliter/minute (calculated by the Cockcroft and Gault formula) and/or patients on dialysis\n* Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening\n* Allergic reaction to any glucagon like peptide-1 (GLP-1) agonist in the past (for example, exenatide, liraglutide) or to metacresol\n* Additional exclusion criteria at the end of the run-in phase: informed consent withdrawal (patient not willing to continue or failed to return); lack of compliance during the single-blind placebo run-in phase (\\>2 injections missed); and patient with any adverse event which precludes the inclusion in the study, as assessed by the Investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Sciences & Operations","affiliation":"Sanofi","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Sanofi-Aventis Administrative Office","city":"Tokyo","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}}]},"referencesModule":{"references":[{"pmid":"26342556","type":"RESULT","citation":"Seino Y, Yabe D, Takami A, Niemoeller E, Takagi H. Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan. J Diabetes Complications. 2015 Nov-Dec;29(8):1304-9. doi: 10.1016/j.jdiacomp.2015.07.003. Epub 2015 Jul 6."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 75 patients were screened of which 6(8.0%) were screen failures; main reasons for screen failure:glycosylated hemoglobin being out of defined protocol range (\\>=7% and \\<=10%) and use of an antidiabetic agent other than a sulfonylurea or alpha-glucosidase inhibitor within 3 months prior to screening. A total of 69 patients were randomized.","recruitmentDetails":"The study was conducted at 9 centers in Japan between May 09, 2009 and January 22, 2011. The overall duration of treatment was at least 76 weeks (52-week open-label treatment; 24-week open-label extension treatment).","groups":[{"id":"FG000","title":"Lixisenatide (Two-step Titration)","description":"2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment."},{"id":"FG001","title":"Lixisenatide (One-step Titration)","description":"1-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 2 weeks, then 20 mcg QD up to end of treatment."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Randomized.","numSubjects":"33"},{"groupId":"FG001","numSubjects":"36"}]},{"type":"Safety Population","achievements":[{"groupId":"FG000","comment":"All patients who were exposed to at least 1 dose, regardless of amount of treatment administered.","numSubjects":"33"},{"groupId":"FG001","numSubjects":"36"}]},{"type":"Modified Intent-to-Treat(mITT)Population","achievements":[{"groupId":"FG000","comment":"All patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment.","numSubjects":"33"},{"groupId":"FG001","numSubjects":"36"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"27"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"9"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Familial and Personal Reasons","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.","groups":[{"id":"BG000","title":"Lixisenatide (Two-step Titration)","description":"2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment."},{"id":"BG001","title":"Lixisenatide (One-step Titration)","description":"1-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 2 weeks, then 20 mcg QD up to end of treatment."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"69"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.9","spread":"9.0"},{"groupId":"BG001","value":"60.4","spread":"8.2"},{"groupId":"BG002","value":"58.7","spread":"8.7"}]}]}]},{"title":"Gender","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"11"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"58"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Race: Asian/Oriental","categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"69"}]}]},{"title":"Ethnicity: Non Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"69"}]}]}]},{"title":"Glycosylated Hemoglobin (HbA1c)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"percentage of hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.35","spread":"0.82"},{"groupId":"BG001","value":"8.12","spread":"0.68"},{"groupId":"BG002","value":"8.23","spread":"0.76"}]}]}]},{"title":"Fasting Plasma Glucose (FPG)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"millimole per liter (mmol/L)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9.91","spread":"1.91"},{"groupId":"BG001","value":"9.16","spread":"1.92"},{"groupId":"BG002","value":"9.52","spread":"1.94"}]}]}]},{"title":"Body Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilogram (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70.75","spread":"19.21"},{"groupId":"BG001","value":"66.74","spread":"11.14"},{"groupId":"BG002","value":"68.66","spread":"15.54"}]}]}]},{"title":"Body Mass Index (BMI)","description":"BMI was calculated by dividing body weight by the height squared.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilogram per square meter (kg/m^2)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25.16","spread":"5.27"},{"groupId":"BG001","value":"24.81","spread":"3.68"},{"groupId":"BG002","value":"24.98","spread":"4.48"}]}]}]},{"title":"Duration of Diabetes","description":"Duration of diabetes is reported at screening.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.05","spread":"6.38"},{"groupId":"BG001","value":"9.03","spread":"7.87"},{"groupId":"BG002","value":"8.56","spread":"7.16"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"SECONDARY","title":"Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of All Patients During On-Treatment Period Assessed Through Adverse Events Collection and Vital Signs, ECG and Laboratory Monitoring","description":"Overview of adverse event profile is reported in terms of percentage of patients with TEAEs during the on-treatment period: any TEAE; any serious TEAE; any TEAE leading to death; any TEAE leading to permanent treatment discontinuation. The on-treatment period was the time from the first dose of study drug up to 3 days after the last dose at Week 76.","populationDescription":"Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered. Analysis was done on the overall group (pooled data from the 2-step and 1-step titration arms) as pre-specified","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"First dose of study drug up to 3 days after the last dose of study drug at Week 76 or early withdrawal","groups":[{"id":"OG000","title":"Lixisenatide (Combined)","description":"Included all patients who received 2-step initiation regimen of lixisenatide or 1-step initiation regimen of lixisenatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"}]}],"classes":[{"title":"Any TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"91.3"}]}]},{"title":"Any Serious TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"4.3"}]}]},{"title":"Any TEAE Leading to Death","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Any TEAE Leading to Treatment Discontinuation","categories":[{"measurements":[{"groupId":"OG000","value":"14.5"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Patients Requiring Rescue Therapy","description":"Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values - from Week 4 to Week 8: fasting SMPG/FPG \\>270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\>8.5%, from Week 24 to end of treatment (Week 76): fasting SMPG/FPG \\>180 mg/dL (10.0 mmol/L) or HbA1c \\>8%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","populationDescription":"mITT population.Analysis was done on the overall group (pooled data from the 2-step and 1-step titration arms) as pre-specified","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline up to Week 52, Baseline up to Week 76","groups":[{"id":"OG000","title":"Lixisenatide (Combined)","description":"Included all patients who received 2-step initiation regimen of lixisenatide or 1-step initiation regimen of lixisenatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"}]}],"classes":[{"title":"Baseline up to Week 52","categories":[{"measurements":[{"groupId":"OG000","value":"17.4"}]}]},{"title":"Baseline up to Week 76","categories":[{"measurements":[{"groupId":"OG000","value":"23.2"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia for the One-Step and Two-Step Titration Arms During 24-Week Treatment Period","description":"Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose less than 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.","populationDescription":"Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"First dose of study drug up to 3 days after the last dose of study drug at Week 24 or early withdrawal","groups":[{"id":"OG000","title":"Lixisenatide (Two-step Titration)","description":"2-step initiation regimen of lixisenatide."},{"id":"OG001","title":"Lixisenatide (One-step Titration)","description":"1-step initiation regimen of lixisenatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"36"}]}],"classes":[{"title":"Symptomatic Hypoglycemia","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Severe Symptomatic Hypoglycemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) for All Patients at Week 52 and 76","description":"Absolute change = HbA1c value at week of assessment (Week 52/Week 76) minus HbA1c value at baseline. The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","populationDescription":"mITT population. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period and \"n\" = patients with HbA1c assessment for the specified category. Analysis was done on the overall group (pooled data from the 2-step and 1-step titration arms) as pre-specified","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of hemoglobin","timeFrame":"Baseline, Week 52, 76","groups":[{"id":"OG000","title":"Lixisenatide (Combined)","description":"Included all patients who received 2-step initiation regimen of lixisenatide or 1-step initiation regimen of lixisenatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"title":"Week 52 (n=47, observed cases)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"0.96"}]}]},{"title":"Week 76 (n=33, observed cases)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 52 and 76","description":"The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","populationDescription":"mITT population. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period and \"n\" = patients with HbA1c assessment for the specified category. Analysis was done on the overall group (pooled data from the 2-step and 1-step titration arms) as pre-specified","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 52, 76","groups":[{"id":"OG000","title":"Lixisenatide (Combined)","description":"Included all patients who received 2-step initiation regimen of lixisenatide or 1-step initiation regimen of lixisenatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"title":"Week 52 (n=47, observed cases)","categories":[{"measurements":[{"groupId":"OG000","value":"40.4"}]}]},{"title":"Week 76 (n=33, observed cases)","categories":[{"measurements":[{"groupId":"OG000","value":"27.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 52 and 76","description":"The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","populationDescription":"mITT population. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period and \"n\" = patients with HbA1c assessment for the specified category. Analysis was done on the overall group (pooled data from the 2-step and 1-step titration arms) as pre-specified","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 52, 76","groups":[{"id":"OG000","title":"Lixisenatide (Combined)","description":"Included all patients who received 2-step initiation regimen of lixisenatide or 1-step initiation regimen of lixisenatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"title":"Week 52 (n=47, observed cases)","categories":[{"measurements":[{"groupId":"OG000","value":"14.9"}]}]},{"title":"Week 76 (n=33, observed cases)","categories":[{"measurements":[{"groupId":"OG000","value":"18.2"}]}]}]},{"type":"PRIMARY","title":"Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of the One-Step and Two-Step Titration Arms Assessed Through Adverse Events Collection and Vital Signs, Electrocardiogram (ECG) and Laboratory Monitoring","description":"Overview of adverse event profile is reported in terms of percentage of patients with treatment emergent adverse events (TEAEs) during the 24-week treatment period: any TEAE; any serious TEAE; any TEAE leading to death; and any TEAE leading to permanent treatment discontinuation.","populationDescription":"Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"First dose of study drug up to 3 days after the last dose of study drug at Week 24 or early withdrawal","groups":[{"id":"OG000","title":"Lixisenatide (Two-step Titration)","description":"2-step initiation regimen of lixisenatide."},{"id":"OG001","title":"Lixisenatide (One-step Titration)","description":"1-step initiation regimen of lixisenatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"36"}]}],"classes":[{"title":"Any TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"81.8"},{"groupId":"OG001","value":"88.9"}]}]},{"title":"Any Serious TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"6.1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any TEAE Leading to Death","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any TEAE Leading to Treatment Discontinuation","categories":[{"measurements":[{"groupId":"OG000","value":"9.1"},{"groupId":"OG001","value":"11.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight for All Patients at Week 52 and 76","description":"Change was calculated by subtracting baseline value from value at week of assessment (Week 52/Week 76). The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","populationDescription":"mITT population. Number of patients analyzed=patients with baseline and at least 1 post-baseline weight assessment during on-treatment period and \"n\" = patients with weight assessment for the specified category. Analysis was done on the overall group (pooled data from the 2-step and 1-step titration arms) as pre-specified","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kilogram","timeFrame":"Baseline, Week 52, 76","groups":[{"id":"OG000","title":"Lixisenatide (Combined)","description":"Included all patients who received 2-step initiation regimen of lixisenatide or 1-step initiation regimen of lixisenatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"title":"Week 52 (n=47, observed cases)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":"2.10"}]}]},{"title":"Week 76 (n=33, observed cases)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.58","spread":"2.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) for All Patients at Week 52 and 76","description":"Change was calculated by subtracting baseline value from value at week of assessment (Week 52/Week 76). The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 1 day after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.","populationDescription":"mITT population. Number of patients analyzed=patients with baseline and at least 1 post-baseline FPG assessment during on-treatment period and \"n\" = patients with FPG assessment for the specified category. Analysis was done on the overall group (pooled data from the 2-step and 1-step titration arms) as pre-specified","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Baseline, Week 52, 76","groups":[{"id":"OG000","title":"Lixisenatide (Combined)","description":"Included all patients who received 2-step initiation regimen of lixisenatide or 1-step initiation regimen of lixisenatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"title":"Week 52 (n=47, observed cases)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"1.54"}]}]},{"title":"Week 76 (n=33, observed cases)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"2.08"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia for All Patients During On-Treatment Period","description":"Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose less than 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.The on-treatment period was the time from the first dose of study drug up to 3 days after the last dose.","populationDescription":"Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered. Analysis was done on the overall group (pooled data from the 2-step and 1-step titration arms) as pre-specified","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"First dose of study drug up to 3 days after the last dose of study drug at Week 76 or early withdrawal","groups":[{"id":"OG000","title":"Lixisenatide (Combined)","description":"Included all patients who received 2-step initiation regimen of lixisenatide or 1-step initiation regimen of lixisenatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"}]}],"classes":[{"title":"Symptomatic hypoglycemia","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Severe symptomatic hypoglycemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"First dose of study drug up to 3 days after the last dose administration up to week 76","description":"Median exposure to study treatment was 531 and 533 days in lixisenatide two-step titration and lixisenatide one-step titration arms, respectively. The analysis was performed on safety population, defined as all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.","eventGroups":[{"id":"EG000","title":"Lixisenatide (Two-step Titration)","description":"2-step initiation regimen of lixisenatide.","seriousNumAffected":2,"seriousNumAtRisk":33,"otherNumAffected":24,"otherNumAtRisk":33},{"id":"EG001","title":"Lixisenatide (One-step Titration)","description":"1-step initiation regimen of lixisenatide.","seriousNumAffected":1,"seriousNumAtRisk":36,"otherNumAffected":34,"otherNumAtRisk":36}],"seriousEvents":[{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":33},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":33},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]}],"otherEvents":[{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":33},{"groupId":"EG001","numAffected":13,"numAtRisk":36}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":33},{"groupId":"EG001","numAffected":7,"numAtRisk":36}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Hypoglycaemia adverse event is based on investigator reported hypoglycaemia.","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Diabetic retinopathy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Yawning","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":33},{"groupId":"EG001","numAffected":6,"numAtRisk":36}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":3,"numAtRisk":36}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33},{"groupId":"EG001","numAffected":3,"numAtRisk":36}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":3,"numAtRisk":36}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":33},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":33},{"groupId":"EG001","numAffected":18,"numAtRisk":36}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":33},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Cold sweat","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Heat rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Periarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Early satiety","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":4,"numAtRisk":36}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33},{"groupId":"EG001","numAffected":3,"numAtRisk":36}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."},"pointOfContact":{"title":"Trial Transparency Team","organization":"Sanofi","email":"Contact-us@sanofi.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"},{"id":"D006943","term":"Hyperglycemia"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C479460","term":"lixisenatide"}]}},"hasResults":true}